Strengthen Yourself Against Tick-borne Diseases, Covid19, and MSIDS

Richard Horowitz, MD, Bay Area Lyme Advisory Board Member and Director of the Hudson Valley Healing Arts Center

Bay Area Lyme Foundation Advisory Board Member, Richard Horowitz, MD and author of “Why Can’t I Get Better?” speaks about his experience and novel research on Tick-borne Diseases, Fire/Smoke Exposure, Covid19, and Multiple Systemic Infectious Disease Syndrome (MSIDS).

Listen on Apple PodcastsListen on Spotify

Bay Area Lyme Foundation Launches Ticktective™ Podcast

FOR IMMEDIATE RELEASE

Media Contact:
Tara DiMilia, 908-947-0500, tara.dimilia@TMstrat.com

Bay Area Lyme Foundation Launches Ticktective™ Podcast

PORTOLA VALLEY, Calif., September 30, 2020 — Bay Area Lyme Foundation, a leading sponsor of Lyme disease research in the US, announces the launch of the Ticktective podcast and video series.  Ticktective is a Bay Area Lyme Foundation program designed to investigate the latest scientific knowledge and advances in Lyme and tick-borne diseases. The podcast offers insightful discussion with researchers, physicians, patients, and thought leaders in the field.

“Because the science surrounding tick-borne disease is so complex and there are so many unanswered questions, Ticktective aims to share firsthand perspectives about the challenges of Lyme in ways that will intrigue more scientists, physicians and patients to join our battle towards making Lyme disease easy to diagnose and simple to cure,” said Linda Giampa, executive director, Bay Area Lyme Foundation.

There are more than 400,000 people diagnosed with Lyme disease each year in the US, and millions of Americans live with persistent Lyme disease (PLD) caused by an ongoing bacterial infection. The current “gold standard” diagnostic for Lyme disease misses up to 60% of cases of early stage Lyme disease, and

if not treated promptly, Lyme may progress to a debilitating stage, becoming difficult, or impossible, to cure. Bay Area Lyme Foundation has funded over 100 research projects at 37 institutions across the US in a mission to find solutions for these patients.

“I’ve always had an insatiable curiosity, and my own diagnosis of Lyme disease has driven me to use this curiosity to find answers that will help lead to solutions for all tick-borne diseases,” said Ticktective host Lia Gaertner, who is the director of education and outreach for Bay Area Lyme Foundation and holds degrees in environmental science and ethnobotany.

Initial Ticktective interviews include conversations addressing the challenges of developing a diagnostic for Lyme disease, the scientific techniques being used to overcome these challenges, what motivates researchers taking on this challenge, and the frustration of patients.

  • 2020 Emerging Leader Award Winner Jacob Lemieux, MD, DPhil of Harvard University discusses the similarities and difference of Lyme disease and malaria, the promise of next-generation sequencing for developing a diagnostic, his lab’s role in COVID-19 research, and the intersection of COVID-19 and Lyme disease.
  • 2020 Emerging Leader Award Winner Artem Rogovsky, DVM, PhD of Texas A&M University discusses what he learned from radioactive ticks, why he is aiming to develop a direct diagnostic for Lyme, and how a conversation at a kids’ birthday party ignited the innovative idea for this diagnostic concept.
  • Liz Horn, PhD, MBI is principal investigator for the Lyme Disease Biobank, which aims to enable and accelerate research by providing scientists with the biological samples needed to conduct important experiments. The Biobank has enrolled over 900 participants and currently supports more than 55 research projects.
  • Singer-songwriter Dana Parish, who not only has numerous chart-topping singles, but has also become a strong advocate for people with Lyme disease after a tick bite in 2014 that progressed to a persistent infection despite antibiotic treatment. She discusses how she is “fighting the good fight,” and making progress in her personal battle and for the cause.

“I was driven to become a songwriter as I wanted to make people feel understood, knowing that the best songs are personal yet universal. With that same spirit, it’s been vital to me to use my voice to be honest about what I’ve learned about the travesty of tick-borne diseases. In an area of medicine filled with misinformation, Ticktective is bringing valuable insights and help straight to the Lyme community. I’m thrilled to have had the opportunity to share my Lyme experience with listeners of Ticktective,” said Parish, whom Gaertner refers to as a fierce champion for the under-represented Lyme community.

Listen to the Ticktective podcast here. Check out other resources of Bay Area Lyme Foundation, including printable fact sheets, videos, educational tools and more, and follow us on and Facebook, Twitter, LinkedIn and Instagram.

About Lyme Disease
The most common vector-borne infectious disease in the country, Lyme disease is a potentially disabling infection caused by bacteria transmitted through the bite of an infected tick to people and pets. If caught early, most cases of Lyme disease can be effectively treated, but it is commonly misdiagnosed due to lack of awareness and unreliable diagnostic tests. There are more than 400,000 new cases of Lyme disease each year, according to statistics released in 2018 by the CDC. As a result of the difficulty in diagnosing and treating Lyme disease, more than one million Americans may be suffering from the impact of its debilitating long-term symptoms and complications, according to Bay Area Lyme Foundation estimates.

About Bay Area Lyme Foundation
Bay Area Lyme Foundation, a national organization committed to making Lyme disease easy to diagnose and simple to cure, is a leading public not-for-profit sponsor of innovative Lyme disease research in the US.  A 501c3 non-profit organization based in Silicon Valley, Bay Area Lyme Foundation collaborates with world-class scientists and institutions to accelerate medical breakthroughs for Lyme disease. It is also dedicated to providing reliable, fact-based information so that prevention and the importance of early treatment are common knowledge. A pivotal donation from The LaureL STEM Fund covers overhead costs and allows for 100% of all donor contributions to Bay Area Lyme Foundation to go directly to research and prevention programs. For more information about Lyme disease or to get involved, visit www.bayarealyme.org or call us at 650-530-2439.

###

Lyme Persistence and COVID “Long-Haulers”

Dana Parish, Bay Area Lyme Advisory Board Member (Co-author of "Chronic" and SonyATV singer/ songwriter)

Bay Area Lyme Foundation Advisory Board Member, “Chronic” co-author and SonyATV singer/songwriter, Dana Parish, shares her perspective on chronic diseases, autoimmunity, COVID-19, and speaking out in the face of adversity. “Chronic: The Hidden Cause of the Autoimmune Pandemic and How to Get Healthy Again” is available for purchase on Amazon here.

Listen on Apple PodcastsListen on SpotifyListen on Google Podcasts

Jacob Lemieux, MD, DPhil and Artem Rogovskyy, DVM, PhD Named Recipients of Bay Area Lyme Foundation’s 2020 Emerging Leader Award

FOR IMMEDIATE RELEASE

Media Contact:
Tara DiMilia, 908-947-0500, tara.dimilia@TMstrat.com

Jacob Lemieux, MD, DPhil and Artem Rogovskyy, DVM, PhD Named Recipients of Bay Area Lyme Foundation’s 2020 Emerging Leader Award

Biobank Samples to Aid 2020 Emerging Leader Award Winners in Discovery of New Rapid and Sensitive Diagnostics for Lyme Disease Testing

PORTOLA VALLEY, Calif., August 11, 2020 — Bay Area Lyme Foundation, a leading sponsor of Lyme disease research in the U.S., announces the recipients of the 2020 Emerging Leader Awards, which are designed to support promising scientists who represent the future of Lyme disease-research leadership. Jacob Lemieux, MD, DPhil of Harvard and Massachusetts General Hospital, and Artem Rogovskyy, DVM, PhD of Texas A&M University will each receive $100,000 toward the development of novel direct-detection diagnostic approaches for Lyme disease. Both researchers will utilize biological samples from the Lyme Disease Biobank, a program of the Bay Area Lyme Foundation, working to accelerate research of Lyme disease and other tick-borne infections. Lyme disease is a potentially disabling infection impacting more than 400,000 Americans each year.

“The value of research proposed by our grant recipients is vital to our mission of making Lyme disease easy to diagnose and simple to cure.  In this year of COVID-19, we are pleased to have the opportunity to continue our grant program to fund the important work of these scientists addressing the most crucial requirement for Lyme disease – an accurate diagnostic test,” said Linda Giampa, executive director, Bay Area Lyme Foundation.

Lyme Diagnostics, Radioactive Ticks, and More

Artem Rogovsky, DVM, PhD (Texas A & M University)

Bay Area Lyme’s 2020 Emerging Leader Award Winner, Artem Rogovsky, DVM, PhD, of the Department of Veterinary Pathobiology, College of Veterinary Medicine & Biomedical Sciences, Texas A&M University, discusses radioactive ticks, Lyme diagnostics, and how a kid’s birthday party can lead to novel research.

Listen on Apple PodcastsListen on SpotifyListen on Google Podcasts

Lyme Biobanking & Lyme Diagnostics

Liz Horn, PhD, MBI (Lyme Disease Biobank)

Principal Investigator for the Bay Area Lyme Disease Biobank, Liz Horn, PhD, MBI, discusses the Biobank which has enrolled over 900 participants, supporting over 50 research projects so far. They support research projects across the nation by providing precious serum, whole blood, urine and tissue samples to researchers.

Listen on Apple PodcastsListen on SpotifyListen on Google Podcasts

New Therapeutics for Infectious Diseases

– Wendy Adams, Research Grant Director, Bay Area Lyme Foundation

This pandemic has brought many different modalities in diagnostics, drug development and vaccines to the popular press. In the Tick-borne Disease (TBD) community, we have seen the issues that arise when the timely diagnosis and treatment of infectious disease are hampered by insensitive diagnostics and ineffective treatments.

It bears repeating however, that drugs that fight the infection in question (antibiotics, antiparasitics, or antivirals) are a large part of any eventual solution to an outbreak, especially in advance of a vaccine (see HIV). Antimicrobial therapeutics help keep the pathogen from replicating uncontrolled, allowing the complicated immune system processes to catch up to it, control it and then eradicate it.

One specific treatment modality is being widely discussed: monoclonal antibodies (mAbs). These are the drugs upon which the whole biotech industry and companies like Genentech, Biogen and Amgen were literally built. Six out of the top 10 drugs by sales are mAbs, mostly for oncology and autoimmune disease indications. However, mAbs have not been commonly used for infectious disease (with one major exception we’ll talk about later).

What are monoclonal antibodies? How do they work?

Antibodies are proteins made by the mammalian immune system. They are a workhorse of the acquired immune response and fight specific antigens, which can be anything from an invading pathogen to an aberrant cell or cytokine that needs destruction. Monoclonal antibodies as a drug class are also very specific and only bind to one antigen. They can bind to a single receptor on the outside of a cell, so that cell can’t receive or send out a message. Or the cell can be tagged so the immune system recognizes the cell as foreign and can destroy it. Binding only one target is important to reduce side effects caused by binding to multiple targets.

Lyme Disease Biobank Expands Into San Diego

FOR IMMEDIATE RELEASE

Media Contact:
Tara DiMilia, 908-947-0500, tara.dimilia@TMstrat.com

Lyme Disease Biobank Expands Into San Diego

Legislative Commendations Support Importance of New Collection Site’s Efforts To Elevate Research

San Diego, CA, March 6, 2020—Bay Area Lyme Foundation, a leading sponsor of Lyme disease research in the U.S., announces the opening of the San Diego collection site of the Bay Area Lyme Foundation’s Lyme Disease Biobank, which is the first program to provide researchers with blood and urine samples from people with early Lyme disease from multiple endemic regions across the country. Congressman Scott Peters and Council member Chris Cate are scheduled to speak at the ribbon-cutting ceremony for the new collection site, and Council President Pro Tem Barbara Bry, Senator Toni Atkins, and Assembly member Todd Gloria will send representatives to issue commendations to support this event.

“Lyme disease is a growing problem in the County of San Diego, because many of our residents travel to or relocate from other more highly endemic areas and it is also possible to be infected locally,” said Sharon Wampler, PhD, who was instrumental in bringing Bay Area Lyme Foundation’s Lyme Disease Biobank to San Diego. “As a world-class hub for research and innovation, we can be part of the solution. This biobank is an important resource which will help researchers answer many current scientific questions about tick-borne diseases.”

New Study Shows Less Than One-Third of Lyme Disease Test Results are Accurate for Patients with Lyme Rash

FOR IMMEDIATE RELEASE

Media Contact:
Tara DiMilia, 908-947-0500, tara.dimilia@TMstrat.com

New Study Shows Less Than One-Third of Lyme Disease Test Results are Accurate for Patients with Lyme Rash

Journal of Clinical Microbiology Publishes Lyme Disease Biobank Data Describing Samples Available for Research on Tick-Borne Infections

Portola Valley, Calif., February 26, 2020—Bay Area Lyme Foundation, a leading sponsor of Lyme disease research in the U.S., announces results published in the Journal of Clinical Microbiology, a journal of the American Society for Microbiology, that point to limitations of currently available diagnostic tests for early-stage Lyme disease and highlight the need for more research toward improved diagnostics and treatments. Among the findings, the Centers for Disease Control’s Standard Two-tier Testing Algorithm (STTTA) for Lyme disease failed to accurately diagnose 71% of blood samples from individuals presenting with a Lyme rash, also known as an erythema migrans, greater than 5 cm in endemic areas. These samples are part of the Lyme Disease Biobank (LDB), which was founded to catalyze new research in the understanding, diagnosis and treatment of Lyme disease and other tick-borne infections. Samples are available for research use through an application process to scientists who already work in tick-borne infections, as well as those new to the field.